Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of tirzepatide for reduction of morbidity and mortality in adults with obesity
MOH_2022-08-23_011995Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Tirzepatide with Placebo (2 arms). Started Sep 2022; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on MOH_2022-08-23_011995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-23_011995.